185 related articles for article (PubMed ID: 25399584)
1. The glioblastoma vasculature as a target for cancer therapy.
Dimberg A
Biochem Soc Trans; 2014 Dec; 42(6):1647-52. PubMed ID: 25399584
[TBL] [Abstract][Full Text] [Related]
2. [The stem cell niche in glioblastoma: from fundamental aspects to targeted therapies].
Turpin A; Sharif A; Stoven L; Blond S; Maurage CA; Le Rhun É
Bull Cancer; 2015 Jan; 102(1):24-33. PubMed ID: 25609493
[TBL] [Abstract][Full Text] [Related]
3. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK; Engelhard HH; Lakka SS
Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation.
Takano S
Brain Tumor Pathol; 2012 Apr; 29(2):73-86. PubMed ID: 22218709
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization.
Dieterich LC; Mellberg S; Langenkamp E; Zhang L; Zieba A; Salomäki H; Teichert M; Huang H; Edqvist PH; Kraus T; Augustin HG; Olofsson T; Larsson E; Söderberg O; Molema G; Pontén F; Georgii-Hemming P; Alafuzoff I; Dimberg A
J Pathol; 2012 Nov; 228(3):378-90. PubMed ID: 22786655
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
Rose SD; Aghi MK
Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
[No Abstract] [Full Text] [Related]
7. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
Gerstner ER; Emblem KE; Sorensen GA
Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
9. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
[TBL] [Abstract][Full Text] [Related]
10. Metabolic modulation of glioblastoma with dichloroacetate.
Michelakis ED; Sutendra G; Dromparis P; Webster L; Haromy A; Niven E; Maguire C; Gammer TL; Mackey JR; Fulton D; Abdulkarim B; McMurtry MS; Petruk KC
Sci Transl Med; 2010 May; 2(31):31ra34. PubMed ID: 20463368
[TBL] [Abstract][Full Text] [Related]
11. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
de Boüard S; Guillamo JS
Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
[TBL] [Abstract][Full Text] [Related]
12. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
Henriksson R; Bergström P; Johansson M; Sandström M
Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
[No Abstract] [Full Text] [Related]
13. Vasculogenic mimicry-potential target for glioblastoma therapy: an in vitro and in vivo study.
Chen Y; Jing Z; Luo C; Zhuang M; Xia J; Chen Z; Wang Y
Med Oncol; 2012 Mar; 29(1):324-31. PubMed ID: 21161444
[TBL] [Abstract][Full Text] [Related]
14. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Sorensen AG; Emblem KE; Polaskova P; Jennings D; Kim H; Ancukiewicz M; Wang M; Wen PY; Ivy P; Batchelor TT; Jain RK
Cancer Res; 2012 Jan; 72(2):402-7. PubMed ID: 22127927
[TBL] [Abstract][Full Text] [Related]
15. Glioma stem cell maintenance: the role of the microenvironment.
Heddleston JM; Hitomi M; Venere M; Flavahan WA; Yang K; Kim Y; Minhas S; Rich JN; Hjelmeland AB
Curr Pharm Des; 2011; 17(23):2386-401. PubMed ID: 21827414
[TBL] [Abstract][Full Text] [Related]
16. Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment.
Gao H; Yang Z; Cao S; Xiong Y; Zhang S; Pang Z; Jiang X
Biomaterials; 2014 Feb; 35(7):2374-82. PubMed ID: 24342723
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
Chinot OL
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma Stem Cells and Their Microenvironment.
Sattiraju A; Sai KKS; Mintz A
Adv Exp Med Biol; 2017; 1041():119-140. PubMed ID: 29204831
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.
von Baumgarten L; Brucker D; Tirniceru A; Kienast Y; Grau S; Burgold S; Herms J; Winkler F
Clin Cancer Res; 2011 Oct; 17(19):6192-205. PubMed ID: 21788357
[TBL] [Abstract][Full Text] [Related]
20. Fewer dollars, more sense.
Garfield DH; Hercbergs A
J Clin Oncol; 2008 Nov; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
[No Abstract] [Full Text] [Related]
[Next] [New Search]
